Please login to the form below

Not currently logged in
Email:
Password:

Impact Biomedicines

This page shows the latest Impact Biomedicines news and features for those working in and with pharma, biotech and healthcare.

Celgene boosts CAR-T stake again with Bluebird Bio deal

Celgene boosts CAR-T stake again with Bluebird Bio deal

We believe this therapy has the potential to significantly impact the treatment approach and outcomes for patients with multiple myeloma,” said Nadim Ahmed, head of Celgene’s haematology and oncology division. ... and a $1.1bn agreement to acquire

Latest news

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Impact Biomedicines for a potential $7bn in early January and then it scooped up the remaining 90% of its CAR-T and TCR technology partner Juno Therapeutics for $9bn. ... Acquisition company -  remaining 90%. 9, 000. Impact Biomedicines/ Celgene.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

The importance of co-creation with patients
Overcoming the barriers...
Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics